Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 5, Issue 5, 1998, Pages 285-299

  Idilman, R ^a,b   De Maria, N ^a   Colantoni, A ^a   Van Thiel, D H ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cancer; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver; Virus

Indexed keywords

CYCLIN A; GROWTH FACTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

CANCER INCIDENCE; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NECROSIS; NONHUMAN; ONCOGENE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; GENES, P53; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; ONCOGENES; PREVALENCE; RISK FACTORS; TRANS-ACTIVATION (GENETICS); VIRUS INTEGRATION;

EID: 0031679781     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00116.x     Document Type: Review

References (86)

1. Busuttil RW, Farmer GD. The surgical treatment of primary hepatobiliary malignancy. Liver Transplant Surg 1996; 2: S114-S130.
2. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in Southern African Blacks. Gastroenterology 1997; 112: 184-187.
3. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 30: 347-354.
4. Colombo M, Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236.
5. Blum HE. Does hepatitis C virus cause hepatocellular carcinoma? Hepatology 1994; 19: 251-258.
6. Rowley JD. Molecular cytogenetics. Cancer Res 1990; 50: 3816-3825.
7. Schimke RT. The search for early genetic events in tumorigenesis. Cancer Cells 1990; 2: 149-151.
8. Hui A, Sakamoto M, Kanai Y, Ino Y, Gotoh M. Inactivation of p16 in hepatocellular carcinoma. Hepatology 1996; 24: 575-579.
9. Scaglioni PP, Melegari M, Wonds JR. Recent advances in the molecular biology of hepatitis B virus. Bailliere's Clin Gastroenterol 1996; 10: 207-225.
10. Gust ID, Burrel CJ, Coulepis AG. Taxonomic classification of human hepatitis B virus. Intervirology 1986; 25: 14-29.
11. Maynard JE, Hepatitis B. Global importance and need for control. Vaccine 1990; 8: S18-S20.
12. Rogler CE. Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. In: Mason WS, Seager C, eds. Hepadnavirus Molecular Biology and Pathogenesis. Berlin: Springer-Verlag, 1991: 102-140.
13. Brechot C. Hepatitis B and C viruses and primary liver cancer. Bailliere's Clin Gastroenterol Viral Hep 1996; 10: 335-373.
14. Paterlini P, Poussin K, De Mitri S. Rate of persistence, structure, and expression of HBV genome in HCC developing in HBs-Ag negative patients. In: Nishioka K, Suzuki H, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer Verlag 1994: 757-762.
15. Brechot C. Hepatitis B virus and hepatocellular carcinoma. HBV-DNA status and its implications. J Hepatol 1987; 4: 269-279.
16. Chen P-J, Chen D-S, Lai M-Y et al. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989; 96: 527-529.
17. Lugassy C, Bernuau J, Thiers V et al. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987; 155: 64-71.
18. Esumi M, Tanaka Y, Tozuka S. Clonal state of human hepatocellular carcinoma and non-tumorous hepatocytes. Cancer Chemother Pharmacol 1989; 23: S1-S4.
19. Koshy R, Maupas P, Muller R, Hofschneider PH. Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues. J Gen Virol 1981; 57: 95-102.
20. Ochiya T, Tsurimoto T, Ueda K, Okubo K, Shiozawa M, Matsubara K. An in vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc Natl Acad Sci USA 1989; 86: 1875-1879.
21. Hino O, Ohtake K, Rogler CE. Features of two hepatitis B virus DNA integrations suggest mechanism of HBV integration. J Virol 1989; 63: 2638-2643.
22. Slagle BL, Zhou YZ, Butel JS. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res 1991; 51: 49-54.
23. Robinson WS. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med 1994; 45: 297-323.
24. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991; 254: 1153-1160.
25. Twu JS, Schloemer RH. Transcriptional transactivating function of hepatitis B virus. J Virol 1987; 61: 3448-3453.
26. Lo SJ, Chien ML, Lee YH. Characteristics of the X gene of hepatitis B virus. Virology 1988; 167: 289-295.
27. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBX uses a tumour promoter signaling pathway. Nature 1993; 361: 742-745.
28. Wollersheim M, Debelka U, Hofschneider PH. A transactivating function encoded by the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988; 3: 545-549.
29. Kim CM, Koike K, Saito I, Miyamura T, Jay G, HBX gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320.
30. Wang W, London WT, Fietelson MA. HBx antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991; 51: 4971-4977.
31. Diamantis I, McGandy CE, Chen TJ, Liaw YF, Gudat F, Bianchi L. HBX gene expression in hepatocellular carcinoma. J Hepatol 1992; 15: 400-403.
32. Raney AK, Milich DR, Eason A, McLachlan A. Differentiation-specific transcriptional regulation of the hepatitis B virus large surface antigen gene in human hepatoma cell lines. J Virol 1990; 64: 2360-2368.
33. Robinson WS. Hepadnaviridae and their Replication, 2nd edn. New York: Raven Press, 1990.
34. Maguire HF, Hoeffler JP, Siddiqui A. HBV-X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991; 252: 842-844.
35. Colgrove R, Simon G, Ganem D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol 1989; 63: 4019-4026.
36. Schek N, Bartenschlager R, Kuhn C, Schaller H. Phosphorylation and rapid turnover of hepatitis B virus x protein expressed in HepG2 cells from a recombinant vaccinia virus. Oncogene 1991; 6: 1735-1744.
37. Hsu IC, Tokiwa T, Bennet H, Metcalf RA, Welsh JA. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993; 14: 987-992.
38. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980-1981.
39. Bressac B, Kew M. Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431.
40. Ozturk M, Bressac B, Puisieux A. Kew M. Volkmann M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338: 1356-1359.
41. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus x protein and hepatocarcinogenesis. J Cancer Res Clin Oncol 1995; 121: 595-601.
42. Henkler F, Waseem N, Golding HC, Alison MR, Koshy R. Mutant p53 but not hepatitis B virus x protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res 1995; 55: 6084-6091.
43. Paterlini P, Flejou JF, De Mitri MS, Pisi E, Franco D. Structure and expression of the cylin A gene in human primary liver cancer. J Hepatol 1995; 23: 47-52.
44. Wang J, Chenivesse X, Henglein B, Brechot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343: 555-557.
45. Bandara L, Adamczewski J, Hunt T, La Thangue N. Cyclin A and retinoblastoma gene product complex with a common transcription factor. Nature 1991; 352: 249-251.
46. Hsia CC, Di Bisceglie AM, Kleiner DE, Farshid M. RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. J Med Virol 1994; 44: 67-73.
47. Rogler CE, Chisari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis 1992; 12: 265-278.
48. Yang DY, Rogler CE. Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing 'in situ' hybridization and immunocyto-chemistry. Carcinogenesis 1991; 12: 1893-1901.
49. Su Q, Liu YF, Zhang JF, Zhang SX, Li DF. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma. Hepatology 1994; 19: 788-799.
50. Popper H, Shih JWK, Gerin JL, Wang DC, Hoyer BH. Woodchuck hepatitis and hepatocellular carcinoma: Correlation of histologic with virologie observations. Hepatology 1981; 1: 91-98.
51. Fu XX, Su CY, Lee Y et al. Insulin-like growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol 1988; 62: 3422-3430.
52. Mead JE, Fausto N. Transforming growth factor α may be physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 1989; 86: 1558-1568.
53. Yeh J, Yeh YC. Transforming growth factor α and human cancer. Biomed Pharmacother 1989; 43: 651-660.
54. Hsia CC, Axiotis CA, Di Bisceglie AM, Tabor E. Transforming growth factor-alpha in human hepatocellular carcinoma and co-expression with hepatitis B surface antigen in adjacent liver. Cancer 1992; 70: 1049-1056.
55. Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factor α and β and the epidermal growth factor receptor by human tumors. Cancer Res 1987; 47: 707-712.
56. Shirai Y, Kawata S, Ito N et al. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992; 83: 676-679.
57. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI. Regulation of transforming growth factor β1 expression by the hepatitis B virus x transactivator. J Clin Invest 1996; 97: 388-395.
58. Pascale RM, Simile MM, Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Research 1993; 13: 1341-1356.
59. Pasquinelli C, Bhavani K, Chisari FV. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenecis in hepatitis B virus transgenic mice. Cancer Res 1992; 52: 2823-2829.
60. Zhang X, Huang D, Qiu D, Chiu J. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene 1990; 5: 909-914.
61. Balsano C, Avantaggiati ML, Natoli G, De Marzio E, Elfassi E. Transactivation of c-fos and c-myc protooncogenes by both full-length and truncate versions of the HBV-x protein. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991: 572-576.
62. Koshy R, Meyer M, Kekule AS, Lauer U, Caselmann WH. Altered functions of hepatitis B virus proteins as a consequence of viral DNA integration may lead to hepatocyte transformation. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991: 566-572.
63. Moses HL. Transforming growth factors and cancer: new insights. Proc Am Assoc Cancer Res 1992; 33: 560.
64. Tabor E. Tumor suppressor genes, growth factor genes and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994; 42: 357-365.
65. Ghebranious N, Sell S. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 1998; 27: 383-391.
66. Cova L, Wild CP, Mehrotra R et al. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks. Cancer Res 1990; 50: 2156-2163.
67. Dunsford HA, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 1990; 50: 3400-3407.
68. Smith DB, Pontisso P. Heterogeneity of hepatitis C virus. Bailliere's Clin Gastroenterol 1996; 10: 243-256.
69. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993; 18: 1326-1333.
70. Edamato Y, Tani M, Kurata T, Abe K. Hepatitis C and B virus infections in hepatocellular carcinoma. Cancer 1996; 77: 1787-1791.
71. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340.
72. Furuya K, Nakamura M, Yamamoto Y, Topel K, Otsuka H. Macroregenerative nodule of the liver. Cancer 1988; 61: 99-105.
73. Theise ND, Schwartz M, Miller C, Thung SN. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explains with cirrhosis. Hepatology 1992; 16: 949-955.
74. Craig JR, Klatt EC, Yu M. Role of cirrhosis and the development of HCC. In: Tabor E, Di Bisceglie AM, Purcell RH, eds. Etiology, Pathology, and Treatment of Hepatocellular Carcinoma in North America. The Woodlands, Portfolio Publishing, 1991: 177-190.
75. Kew MC. The hepatitis C virus and hepatocellular carcinoma. FEMS Microbiol Rev 1994; 14: 211-224.
76. Gerber MA, Shieh CYS, Shim KS, Swan NT, Demetris AJ. Detection of replicative C virus sequences in hepatocellular carcinoma. Am J Pathol 1992; 141: 1271-1277.
77. Horiike N, Nonaka T, Kumamoto I, Kajino K, Onji M. Hepatitis C virus plus and minus-strand RNA-i hepatocellular carcinoma and adjoining nontumorous liver. J Med Virol 1993; 41: 312-315.
78. Haruna Y, Hayashi N, Kamada T, Hytiroglou P, Thung SN. Expression of hepatitis C virus in hepatocellular carcinoma. Cancer 1994; 73: 2253-2258.
79. Takamisawa A, Mori C, Fuke I, Manabe S, Murakami S. Structure and organisation of the hepatitis C virus genemo isolated from human carriers. J Virol 1991; 65: 1105-1113.
80. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994; 54: 231-235.
81. Mahaney K, Tadeschi V, Maertens G et al. Genotypic analyses of hepatitis C virus in American patients. Hepatology 1994; 20: 1405-1411.
82. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohio M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction. Hepatology 1993; 18: 16-20.
83. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Seminars Liver Dis 1995; 15: 64-69.
84. Caselmann WH, Alt M. Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. J Hepatol 1996; 24: S61-S66.
85. Hoofnagle JH. Delta hepatitis and delta virus. In: Seeff LB, Lewis JH, eds. Current Perspectives in Hepatology. New York: Plenum Publishing, 1989: 47-62.
86. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma: prevalence and significance. Arch Intern Med 1993; 153: 1672-1677.